In a significant step towards enhancing patient safety and ensuring rational medication use, the Ministry of Health and Family Welfare has prohibited the manufacture, sale, and distribution of 16 Fixed Dose Combination (FDC) drugs for human use nationwide. This ban, enforced under Section 26A of the Drugs and Cosmetics Act, 1940, is effective immediately. The decision stems from a directive by the Supreme Court, urging a comprehensive review of Fixed Dose Combinations available in the Indian market.
The Drugs Technical Advisory Board (DTAB) responded to the Supreme Court’s directive by forming an Expert Committee to evaluate various FDCs, focusing on their safety, efficacy, and therapeutic value. Following a thorough scientific assessment, the Expert Committee determined that the 16 FDCs lacked sufficient therapeutic justification and could potentially pose health risks. Consequently, the government opted to prohibit these combinations, citing the outweighing health risks compared to benefits.
The banned drugs span diverse therapeutic categories, including dermatological products, pain-relief and antispasmodic medications, and antibiotic-based formulations. The Ministry highlighted that these combinations were deemed irrational and lacked substantial scientific backing. This regulatory action aligns with the government’s commitment to ensuring the availability of safe, effective, and scientifically validated medicines to the public, emphasizing past interventions against irrational drug combinations post extensive scientific scrutiny.
With immediate effect, the manufacture, sale, distribution, and supply of the identified 16 FDCs for human use are banned nationwide. The Ministry has instructed State Drug Controllers, regulatory bodies, and enforcement agencies to rigorously enforce the ban and ensure compliance. Stakeholders such as manufacturers, importers, and distributors have been urged to adhere to the law’s provisions and discontinue the affected products promptly. This move underscores the government’s dedication to evidence-based healthcare, patient safety, and the rational use of medicines in the country.
